Analyzing the Future of Late Stage Chronic Kidney Disease Drugs Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the late stage chronic kidney disease drugs market right now?
In recent times, the market size for drugs for late-stage chronic kidney disease has experienced swift growth. There is a predicted increase from $7.08 billion in 2024 to $7.92 billion in 2025 with a compound annual growth rate (CAGR) of 11.9%. This growth in the historic period has been primarily driven by enhanced diagnostic abilities, rise in the elderly population, higher incidence of diabetes and hypertension, increased understanding of kidney diseases, and an expanded focus on pharmaceutical research and development.
How fast Is the late stage chronic kidney disease drugs market expected to grow, and what’s its future value?
Anticipated to surge in leaps and bounds, the market for end-stage chronic kidney disease drugs is predicted to escalate to a whopping $12.2 billion by 2029, charting a compound annual growth rate (CAGR) of 11.4%. This projected augmentation during the forecast span can largely be contributed to escalating healthcare expenditure, the incorporation of precision medicine methodology, peerless focus on regenerative medicine, an amplified stress on patient-oriented care, and worldwide campaigns boosting kidney disease awareness. Tendencies expected to dominate the forecast era comprise the growth of regenerative medicine treatments, ascension in telemedicine services for managing CKD, the evolution of integrated therapies, emphasis on proactive intervention approaches, and mushrooming interest in biomarker-facilitated diagnostics.
Get your late stage chronic kidney disease drugs market report here!
What are the leading drivers of growth in the late stage chronic kidney disease drugs market?
The widespread incidence of chronic kidney ailments is anticipated to significantly fuel the expansion of the late-stage chronic kidney disease drug market. Chronic kidney conditions encompass a variety of diseases that impair the structural and functional aspects of the kidneys. Late-stage chronic kidney disease drugs are administered to regulate blood pressure in patients and reduce protein loss in order to slow the progression of kidney damage, manage symptoms, and prevent further complications. According to a May 2024 report from the Centers for Disease Control and Prevention (CDC), a public health organization in the US, it is estimated that 14% of American adults – equivalent to about 35.5 million individuals – suffer from chronic kidney diseases. Consequently, the high occurrence of chronic kidney disease is promoting the growth of the late-stage chronic kidney disease drug market.
What are the key segments defining the late stage chronic kidney disease drugs market?
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp
Who are the key players steering the development of the late stage chronic kidney disease drugs market?
Major companies operating in the late stage chronic kidney disease drugs market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc
What emerging trends are influencing the growth of the late stage chronic kidney disease drugs market?
The growing trend of product innovation is omnipresent within the late-stage chronic kidney disease drug market. A primary strategy adopted by leading companies in this industry is the development of novel drugs to maintain their market stance. To illustrate, in February 2022, Bayer, a pharmaceutical and biotechnology firm based in Germany, introduced Kerendia (finerenone) in India. This first-in-class, non-steroidal, selective mineralocorticoid receptor antagonist is intended for use by patients with type two diabetes and chronic renal disease. It functions by inhibiting the excessive activation of the mineralocorticoid receptor (MR), believed to play a part in the progression of chronic kidney disease (CKD) and cardiovascular damage.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12196
Which regions are most influential in expanding the late stage chronic kidney disease drugs market?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Oil And Gas Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-and-gas-global-market-report
Oil Accumulator Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-accumulator-global-market-report
Oil And Gas Pumps Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oil-and-gas-pumps-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
